Sangamo Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and a Favorable Safety Profile

Click here to view

Careers
Clinical Trials
Contact

Science
Programs
Patients
Investors & Media
- Overview
- News Releases
- Events
- Presentations
- ESG
About

Science
Programs
Patients
Investors & Media
- Overview
- News Releases
- Events
- Presentations
- ESG
About

LinkedIn
Twitter

Leadership

Executive Leadership Team
Board of Directors

Executive Leadership Team

Sandy Macrae, M.B., Ch.B., Ph.D.

Chief Executive Officer
Gregory Davis, Ph.D.

Head of Research and Technology
Nathalie Dubois-Stringfellow, Ph.D.

Chief Development Officer
Prathyusha Duraibabu

Chief Financial Officer
Phillip Ramsey

Head of Technical Operations
Stephanie J. Seiler, CLP

Head of Business Development & Alliance Management
Louise Wilkie

Global Corporate Communications and Investor Relations
Scott Willoughby

General Counsel and Corporate Secretary

Board of Directors

H. Stewart Parker

Chair of the Board
Courtney Beers, Ph.D.
Robert Carey
Kenneth Hillan, M.B. Ch.B.
Margaret (Peg) A. Horn, J.D.
Sandy Macrae, M.B., Ch.B., Ph.D.
John Markels, Ph.D.
James R. Meyers
Karen Smith, M.D., Ph.D., M.B.A., LLM

Sign up for email alerts

Company

Science
Programs
Collaborations
Patients
About
Careers
Contact

Latest

News Releases
Events
Science Presentations
Scientific Publications
Corporate Presentations

Resources

Pipeline
Clinical Trials
Media Library
Legal Disclaimer
Privacy Policy

Social

LinkedIn
X

© 2025 Sangamo Therapeutics